Background: Access to medical care vary across the world and is related to different health systems with an impact in recurrence.Objective: To evaluate disparities in breast cancer(BC) diagnosis and treatment between public and private services in southwest Brazil and at two public safety net hospitals in Houston, Texas.Methods: Women diagnosed with BC stages I-III between 2009 to 2011, and treated at the four hospitals in Brazil and two health centers in US were included. All statistical analyses were performed in R studio software, and p<0.05 was considered significant.Results: 1245 women were included: 967 from public health system (PHS) (20.3% from Houston, Texas) and 274 from private system(PS). Recurrence rate was higher in PHS (14.6% vs. 2.6%, p<0.001)

Table 1. Clinical and demographic characteristics of the patients

Characteristics Public (%), n=967 Private (%), n=274 
Discovery of BC       
By patient 530 (54.8) 92 (33.5)   
Routine exam 87 (9) 109 (39.8)   
Screening mammography 270 (27.9) 23 (8.4)   
Other 80 (8.3) 50 (18.3) <0.001 
Initial treatment       
Surgery 687 (71) 241 (88)   
Neo-adjuvant chemotherapy 224 (23.2) 27 (9.8)   
Neo-adjuvant hormone therapy 23 (2.3) 27 (9.8)   
Not available 33 (3.4) 3 (1.1) <0.001 
Clinical Stage       
293 (30.3) 113 (41.2)   
II 342 (35.4) 52 (19)   
III 271 (28) 15 (5.5)   
Unknown 61 (6.3) 94 (34.3) <0.001 
Subtype       
HR+/HER2 - 561 (58) 192 (70.1)   
HR-/HER2+ 108 (11.1) 29 (10.6)   
HR-/HER2+ 76 (7.9) 14 (5.1)   
Triple negative 149 (15.4) 28 (10.2)   
Unknown 73 (7.6) 11 (4) 0.012 
Symptomatic at Diagnosis       
Yes 591 (61.1) 100 (36.5)   
No 306 (31.6) 97 (35.4)   
Unknown 70 (7.2) 77 (28.1) <0.001 
Recurence n=772 n=146   
No 719 (74.4) 193 (70.4)   
Yes 142 (14.6) 7 (2.6)   
Unknown 106 (11) 74 (27) <0.001 
Characteristics Public (%), n=967 Private (%), n=274 
Discovery of BC       
By patient 530 (54.8) 92 (33.5)   
Routine exam 87 (9) 109 (39.8)   
Screening mammography 270 (27.9) 23 (8.4)   
Other 80 (8.3) 50 (18.3) <0.001 
Initial treatment       
Surgery 687 (71) 241 (88)   
Neo-adjuvant chemotherapy 224 (23.2) 27 (9.8)   
Neo-adjuvant hormone therapy 23 (2.3) 27 (9.8)   
Not available 33 (3.4) 3 (1.1) <0.001 
Clinical Stage       
293 (30.3) 113 (41.2)   
II 342 (35.4) 52 (19)   
III 271 (28) 15 (5.5)   
Unknown 61 (6.3) 94 (34.3) <0.001 
Subtype       
HR+/HER2 - 561 (58) 192 (70.1)   
HR-/HER2+ 108 (11.1) 29 (10.6)   
HR-/HER2+ 76 (7.9) 14 (5.1)   
Triple negative 149 (15.4) 28 (10.2)   
Unknown 73 (7.6) 11 (4) 0.012 
Symptomatic at Diagnosis       
Yes 591 (61.1) 100 (36.5)   
No 306 (31.6) 97 (35.4)   
Unknown 70 (7.2) 77 (28.1) <0.001 
Recurence n=772 n=146   
No 719 (74.4) 193 (70.4)   
Yes 142 (14.6) 7 (2.6)   
Unknown 106 (11) 74 (27) <0.001 

. Considering the interval in weeks: symptoms to diagnosis, diagnosis to first treatment (either surgery or neoadjuvant chemotherapy), diagnosis to first systemic treatment, diagnosis to surgical treatment and diagnosis to radiotherapy were longer in public patients (24.1 vs. 8.7; 11.1 vs. 3.5; 18.6 vs. 9.8; 16.9 vs. 5.6; 51.4 vs. 26.1; p<0.001).

Table 2. Delay disparities between public and private health system

  Public Private 
Symptoms to diagnosis       
Number of patients 575 146   
Time (weeks) 24.1 (0.4-104.9) 8.7 (0.0-43.7) <0.001 
Diagnosis to first treatment       
Number of patients 663 180   
Time (weeks) 11.1 (2.0-31.5) 3.5 (0.0-11.0) <0.001 
Diagnosis to first systemic treatment       
Number of patients 526 106   
Time (weeks) 18.6 (2.6-44.7) 9.8 (1.9-29.3) <0.001 
Diagnosis to surgical treatment       
Number of patients 657 178   
Time (weeks) 16.9 (3.4-45.6) 5.6 (0.0-32.9) <0.001 
Diagnosis to radiotherapy       
Number of patients 465 127   
Time (weeks) 51.4 (18.7-88.4) 26.1 (5.6-66.4) <0.001 
  Public Private 
Symptoms to diagnosis       
Number of patients 575 146   
Time (weeks) 24.1 (0.4-104.9) 8.7 (0.0-43.7) <0.001 
Diagnosis to first treatment       
Number of patients 663 180   
Time (weeks) 11.1 (2.0-31.5) 3.5 (0.0-11.0) <0.001 
Diagnosis to first systemic treatment       
Number of patients 526 106   
Time (weeks) 18.6 (2.6-44.7) 9.8 (1.9-29.3) <0.001 
Diagnosis to surgical treatment       
Number of patients 657 178   
Time (weeks) 16.9 (3.4-45.6) 5.6 (0.0-32.9) <0.001 
Diagnosis to radiotherapy       
Number of patients 465 127   
Time (weeks) 51.4 (18.7-88.4) 26.1 (5.6-66.4) <0.001 

In multivariate analysis, PHS (HR 1.72; 95% CI 1.34-1.88; p adj=0.003), presence of symptoms (HR 2.29; 95% CI 1.39-3.78; p adj=0.001), clinical stage III (HR 1.62; 95% CI 1.35-1.93; p adj<0.001), and triple negativity and HER2neu positivity (1.18; 95% CI 1.03-1.35; p adj=0.021) were all associated with a higher recurrence rate.Conclusions: There were significant disparities between PHS and PS. Women in the PHS presented higher rates of recurrence, advanced clinical stages at diagnosis, symptoms and more aggressive subtypes by IHC. additionally, the interval between symptoms to diagnosis and diagnosis to treatments was longer in PHS.

Citation Format: NematiShafaee M, Natal RA, Ramalho S, Dória MT, Conz L, Cabello V, Pavanello M, Mano MS, Linck RDM, Batista LS, Pedro EP, Bines J, de Paula BH, Zucca-Matthes G, Bondy ML, Ellis MJ, Podany E, Debord L, Makawita S, Stewart K, Cabello C. Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-10-15.